---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-001106"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:41:43.299007+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Prelim. Q4 BRIUMVI Rev $103.6M; FY2025 US Revenue Target $525M

## Summary
- Preliminary Q4 2024 BRIUMVI U.S. net product revenue $103.6M; full year 2024 $310M.
- FY2025 target total global revenue ~$540M, including BRIUMVI U.S. net product revenue ~$525M; target opex ~$300M.
- 2025 milestones: commence pivotal program for subcutaneous BRIUMVI; evaluate 30-min infusion; enroll in autoimmune trials.
- Year-end 2024 cash position approx. $310M.
- CEO states 2024 revenue far exceeded initial expectations; BRIUMVI well positioned for continued growth.

## SEC filing metadata
- accession: 0001437749-25-001106
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774925001106/0001437749-25-001106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774925001106/tgtx20250114_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-001106
- JSON: https://secwatch.observer/filing/0001437749-25-001106.json
- Plain text: https://secwatch.observer/filing/0001437749-25-001106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.